Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position

Regulatory News:

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, reports today its annual revenue for the fiscal year ended December 31, 2025, and provides an update on its financial position.

Consolidated Revenue

Poxel generated consolidated revenue of €5 millions¹ for the year ended 31 December 2025, compared with €6.6 million in the corresponding period in 2024, which included a milestone payment of ¥500 million (€3.1 million) from Sumitomo following the achievement of a contractual sales threshold for TWYMEEG^.

Consolidated revenue for fiscal year 2025 fully reflects the ¥873 million in royalties received from Sumitomo Pharma, namely:

• 10% of TWYMEEG net sales in Japan in the first and fourth quarters of 2025, as the ¥5 billion net sales threshold was exceeded in the last quarter of Sumitomo’s 2024–2025 fiscal year, which corresponds to Poxel’s first quarter of 2025, and in the third quarter of Sumitomo’s 2025–2026 fiscal year, which corresponds to Poxel’s fourth quarter of 2025.
• 8% of TWYMEEG net sales in Japan for Poxel’s second and third quarters of 2025.
• However, the ¥5 billion threshold was reached during the fourth quarter of 2025, resulting in the retroactive application of the 10% royalty rate to the second and third quarters. Poxel will therefore receive an additional amount of ¥88 million in respect of the second and third quarters.

Under the license agreement with Merck Serono, Poxel will pay Merck Serono a fixed royalty of 8% calculated on net sales of Imeglimine, regardless of the level of sales. In accordance with the royalty monetization agreement with OrbiMed, net positive royalties will be allocated largely to the redemption of the bonds.

EUR (in thousands)

2025 Q1 3 months

2025 Q2 3 months

2025 Q3 3 months

2025 Q4 3 months

FY 2025 12 months

FY